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Abstract 
Objective: Elevated plasma adrenomedullin (ADM) levels are associated with 
cardiovascular diseases. Single nucleotide polymorphisms (SNPs) in the gene encoding 
ADM (ADM) are associated with plasma ADM levels. The presence of a nuclear factor for 
interleukin-6 (IL-6) expression binding site in the promoter region of the ADM gene 
suggests a possible relationship between the expression of the ADM and IL-6. Therefore, 
we investigated if plasma ADM levels are related to SNPs in the gene encoding IL-6 (IL6).  
Methods: Plasma ADM levels were measured in 476 subjects in the Hong Kong 
Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2). The subjects were genotyped 
for three tagging SNPs in the IL6 gene.  
Results: The minor allele frequencies of the IL6 SNPs rs17147230, rs1800796 and 
rs2069837 were 41.8%, 20.0% and 15.4% respectively. The tagging SNP, rs17147230, was 
associated with plasma ADM levels after adjusting for age and sex (β=-0.096, P=0.034). 
The association was significant in women (β=-0.115, P=0.021) but not in men. Amongst all 
subjects, plasma ADM levels decreased with an increasing number of minor alleles of 
rs17147230 in multivariate analysis (P=0.034). Compared to subjects with the AA genotype, 
subjects with the TT genotype had plasma ADM levels 12.8% lower (95% CI: 0.6%-23.5%, 
P=0.041). Haplotype analysis demonstrated a significant association of the haplotype ACA 
with plasma ADM levels in women (P<0.05).  
Conclusion: Plasma ADM levels are related to the SNP rs17147230 in IL6 gene. The effect 
of the polymorphism on inflammation and cardiovascular disease remains to be determined. 
(242 words)
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Introduction 
Adrenomedullin (ADM) is a vasodilatory peptide initially discovered in human 
pheochromocytoma tissues (1). The gene encoding ADM (ADM) is located on chromosome 
11p15.4, which encodes prepro-ADM, the precursor form of circulating ADM. ADM is both 
a paracrine hormone (2) and an adipokine (3), expressed and secreted in different tissues 
such as the adrenal medulla, heart, kidney and pancreatic islets (4). Plasma ADM levels are 
elevated in hypertension, renal failure, septic shock and type 2 diabetes (T2DM) (5). ADM 
also regulates acute and chronic inflammatory responses (6, 7). 
 
Recently, plasma ADM levels have been suggested as a biomarker to predict cardiovascular 
events or diseases (8). It is important to understand the factors that may account for the 
change in plasma ADM levels, which may be influenced by genetic variants (9). As such, 
factors that could modulate ADM gene expression may alter plasma ADM levels. In the 
discovery of the ADM gene, a nuclear factor for the interleukin-6 expression (NF-IL6) 
binding site was found in the ADM gene promoter region (10). This arouses interest in the 
possibility of an interaction between ADM and IL-6. Indeed, in our previous study, plasma 
IL-6 levels decreased significantly with increasing plasma ADM tertiles (9).  
 
Plasma ADM levels have been shown to correlate with single nucleotide polymorphisms 
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(SNPs) in its gene. Given the presence of a NF-IL6 binding site in ADM gene, which 
implies the regulation of IL-6 and ADM expression by a common nuclear factor, we 
hypothesized that SNPs in the gene encoding IL-6 (IL6) may have an effect on plasma 
ADM levels. The human IL6 gene is located on chromosome 7p21, where several common 
SNPs have been identified in the promoter region that could affect IL6 transcription and 
circulating IL-6 levels (11, 12). Therefore, we investigated the association between SNPs in 
the IL6 gene with plasma ADM levels.  
 
Methods 
Subjects 
The Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) is a prospective 
cohort study of cardiovascular risk factors in a general population. In 1995-1996, a random 
sample of 2,895 subjects were first recruited for CRISPS1. In the period from 2000-2004, 
1,944 subjects were followed up in CRISPS2 (13, 14). Plasma ADM was measured in 476 
randomly selected subjects from the sub-cohort of 1,944 subjects. Written informed consent 
was given by all participants. The study protocol was approved by the Ethics Committee of 
the University of Hong Kong and the institutional review board of the Hong Kong West 
Cluster of Hospitals.  
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SNP selection 
Tagging SNPs in IL6 were selected from the HapMap Han Chinese (phase II data, release 
24) as described previously (15). Four tagging SNPs could capture all six SNPs from the 
5kb region upstream to 2kb downstream region of the gene. The SNP rs2069852 was 
excluded for analysis due to the deviation from Hardy Weinberg equilibrium (P<0.05) after 
genotyping. Three tagging SNPs, which could capture the remaining five out of six 
genotyped SNPs, were selected (position 22,728,345-22,740,141, namely rs17147230, 
rs1800796, and rs2069837) with r²≥ 0.9 and minor allele frequency (MAF) ≥ 0.05 (Figure 
1). Genotyping was performed using the MassARRAY system (Sequenom, San Diego, CA) 
with the iPLEX assay.  
 
Plasma ADM levels and other variables 
Plasma samples underwent extraction and ADM levels were measured by 
radioimmunoassay (RIA) using a method adapted from previous studies (16, 17). Plasma 
ADM immunoreactivity was measured using a commercially available RIA kit from 
Peninsula Laboratories (Belmont, CA, USA) in 235 subjects and Phoenix Pharmaceuticals 
(Burlingame, CA, USA) in 241 subjects, both with the same protocol and internal controls 
were included. Plasma IL-6 was measured in 438 subjects in duplicate using 
high-sensitivity enzyme-linked immunosorbent assay (ELISA) kits (Bender MedSystems 
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GmbH, Vienna, Austria) (18).  
 
Other clinical parameters such as body mass index (BMI), systolic blood pressure (SBP), 
diastolic blood pressure (DBP), post oral glucose tolerance test (OGTT) glucose level, 
homeostatic model assessment of insulin resistance index (HOMA-IR), high-density 
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, adiponectin, 
high-sensitivity C-reactive protein (hsCRP), fibrinogen, alkaline phosphatase (ALP) and 
γ-glutamyl transferase (GGT) were measured as previously described (9, 13, 14, 18). Full 
measurement of glucose level and plasma IL-6 level, complete information on regular 
drinking and exercise status were obtained in 377 out of 476 subjects. Regular drinking was 
defined as drinking alcohol at least once a week. Regular smoking was defined as smoking 
cigarettes currently, based on the criteria of having a habit of consuming cigarettes weekly. 
Regular exercise was defined as doing exercise for at least 30 minutes at least once a week 
in the previous month. Presence of cardiovascular diseases was based on self-reported 
stroke or ischemic heart diseases status from the questionnaire.  
 
Statistical analysis 
Statistical analysis was performed using SPSS 19.0 for Windows (SPSS, Inc., Chicago, IL., 
USA). Normally distributed data were presented as mean ± SD. Variables with skewed 
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distribution were log-transformed before analysis and were presented as geometric mean 
(95% confidence interval). The PLINK program (version 1.0.7) was used to assess the 
overall association of various IL6 SNPs with ADM levels using additive allelic model (19). 
The independent association of plasma ADM level with IL-6 SNPs was assessed by 
multiple linear regression analysis, with adjustment for age and sex in the initial model, 
followed by other biochemical and demographic parameters in the final adjustment model. 
Relationship of ADM level with other confounding factors was also assessed. Correction of 
multiple SNP testing was performed using permutation testing with the simulation repeated 
1,000 times. Assessment of linkage disequilibrium (LD) and haplotype analysis was 
performed using PLINK software. Only haplotypes with frequency > 5% were tested. 
Omnibus testing was first applied to assess the overall P value of the global variation at the 
locus. Then the specific effect of each haplotype was tested by comparing with all other 
haplotypes combined. Sex-specific analysis was carried out using the regression modeling 
and haplotype analysis. The interaction effect of sex was also investigated. For highly 
correlated variables such as BMI and waist circumference, only one was entered into the 
model for analysis to avoid multicollinearity. Percentage changes were expressed for plasma 
IL-6 and ADM for ease of interpretation. 
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Results 
Genotyping of SNPs in IL6 gene 
The MAFs of the IL6 SNPs rs17147230, rs1800796 and rs2069837 were 41.8%, 20.0% and 
15.4% respectively. None of the three SNPs showed significant deviation from the 
Hardy-Weinberg equilibrium (P>0.05). The pairwise linkage disequilibrium (r²) between 
rs17147230 and rs1800796, rs1800796 and rs2069837, and rs17147230 and rs2069837 was 
0.150, 0.728 and 0.081 respectively.  
  
Association analysis and clinical characteristics 
Among the three IL6 SNPs, only rs17147230 was significantly associated with plasma 
ADM levels (β=-0.096, P=0.034) (Figure 2). As shown in Table 1, plasma ADM levels 
significantly decreased from 12.1 pmol/L to 10.6 pmol/L with an increasing number of 
minor T alleles present.The association remained significant after adjusting for other 
clinical parameters shown in Table 1, but further adjustment for plasma IL-6 resulted in loss 
of significance in the association (Table 2). Adjusting for plasma creatinine alone did not 
result in great change in effect size (adjusted r2=0.022), while the association became 
marginally insignificant (P=0.053, data not shown). The association of rs17147230 with 
plasma ADM was significant in women and not in men, but there was no significant 
interaction with sex (P=0.207).  
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 The other two SNPs were not significantly associated with plasma ADM. For rs1800796, 
plasma ADM in subjects with CC, CG and GG genotypes were 11.6, 11.2 and 13.1 pmol/L 
respectively whereas the corresponding levels in subjects with AA, AG and GG genotypes 
at rs2069837 were 11.7, 10.9 and 12.6 pmol/L respectively (both P>0.05 after adjusting for 
age and sex). Other clinical characteristics according to the genotypes of rs17147230 are 
shown in Table 1. HOMA-IR decreased with increasing number of the minor allele T 
(P=0.045), and carriers of the minor T allele of rs17147230 tended to have less regular 
exercise than non-carriers (P=0.042). There was no significant difference in other clinical 
characteristics across different genotypes.   
 
Multivariate analysis of rs17147230 
In multivariate analysis using IL6 SNP as a categorical variable (Supplementary Table S1), 
the presence of two minor T alleles of rs17147230 resulted in -12.8% (95% CI: -23.5%, 
-0.6%) change in plasma ADM levels (P=0.041), after adjusting for age and sex. In 
sex-specific analysis, TT genotype in females resulted in –21.4% (95% CI = -35.7%, -4.0%) 
change in ADM levels (P=0.019), with an effect size much greater than males who only 
showed a 2.2% decrease (P=0.799). The association remained significant after adjusting for 
other clinical parameters, but further adjustment for plasma IL-6 resulted in loss of 
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significance in the association (P=0.076, 0.969 and 0.064 for all subjects, men and women 
respectively). 
 
Haplotype analysis 
After constructing haplotypes for rs17147230, rs1800796 and rs2069837, three haplotypes 
with frequency > 5% were found, namely, ACA, TCA and TGG with a frequency of 54.5%, 
25.5% and 12.0% respectively. Haplotype analysis revealed similar results in which the 
association tended to be more prominent in women than in men (overall P=0.056 and 0.92 
respectively), although the association did not reach statistical significance. In women, the 
haplotype ACA was associated with ADM levels that were higher by 10.6% (95% CI: 0.2%, 
22.1%, P=0.047) compared to all other haplotypes. This compared to a 1.4% increase 
associated with the same haplotype in men (95% CI: -6.4%, 9.8%, P=0.736). 
 
Discussion 
Plasma ADM levels are elevated in cardiovascular disease and diabetes mellitus, and are 
subject to multi-factorial control. The presence of an NF-IL6 binding site in the ADM 
promoter region suggests that the expression of IL-6 and ADM may be related. IL-6 has 
been found to be a regulator of the production of acute phase proteins like CRP and 
fibrinogen (19), which are also inflammatory markers. Genetic variants in IL6 gene are also 
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associated with CRP and fibrinogen levels (16, 21, 22). This study identifies for the first 
time an association between an IL6 SNP and plasma ADM levels. This deepens our 
understanding of the interactions between ADM and other markers of inflammation and 
cardiovascular disease. 
 
Previous studies on IL6 and ADM SNPs have identified SNPs located in the promoter 
region. Due to the presence of a NF-IL6 binding site on both ADM and IL6 genes in the 
promoter region, we may suspect that the association could be due to induction of the 
nuclear factor by plasma IL-6. For instance, a mutation in the NF-IL6 binding site could 
reduce promoter activity and gene transcription (10). The SNP rs17147230 is located at 411 
bp near the 5’ end of IL6 gene while the NF-IL6 binding site is located between –145 
and –158 region (23). Hence, the SNP is not located at the binding site for NF-IL6. 
Nevertheless, this study demonstrates that genetic influence from the IL6 gene outside the 
promoter region could modulate plasma ADM levels. This effect may not be mediated 
through the activation of the NF-IL6 site. We speculate that the effect of rs17147230 may be 
mediated through interacting with an ADM SNP rs4910118 reported in our previous study, 
since interaction analysis showed that the dominant allele of rs4910118 interacted with 
rs17147230 (P<0.025). Further studies are needed to reveal the detailed mechanism of the 
effect on ADM levels. 
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 ADM has been shown to predict dysglycemia development (24), and mid-regional 
pro-adrenomedullin (MR-proADM) had good prognostic value in patients with heart failure 
after an acute myocardial infarction (25). In the light of our new findings, the association of 
ADM levels with IL-6 may help refine the predictive value of ADM in cardiovascular 
diseases. Both plasma ADM and IL-6 levels are elevated in various diseases like heart 
failure and could reflect progression and deterioration of diseases (26, 27). Therefore, a high 
IL-6 level may indicate possible elevation of ADM levels or vice versa. However, we 
previously demonstrated that plasma IL-6 levels correlated with plasma ADM (9), in which 
IL-6 levels decreased with increasing ADM tertiles. This raises the possibility that IL-6 or 
ADM may counter-regulate each other. Determining the sequence of elevation in IL-6 and 
ADM levels might shed light on the causal relationship between IL-6 and ADM and help to 
understand the regulation of inflammation. Interestingly, rs17147230 was associated with 
ADM but not IL-6 levels, the latter was associated with another IL6 SNP rs1800796 in our 
previous study (15). Therefore studying the interaction between the two SNPs may help 
understand the mechanism of the regulation of ADM level by IL-6.    
 
This report is in agreement with previous studies showing a role for the IL6 gene in 
regulating inflammatory biomarkers (20). Various SNPs such as -572G/C and -174G/C in 
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the IL6 promoter have been reported to be associated with inflammation and cardiovascular 
disease (28, 29). But for rs17147230 in this study, it is not a significant predictor of 
cardiovascular diseases according to our results. Nevertheless, genetic polymorphisms 
could only explain a small part of the variation in ADM levels. Clearly, the regulation of 
ADM is subject to other genetic and environmental influences. Recently a report suggested 
the effect of several confounders including age, sex, BMI and estimated glomerular 
filtration rate (eGFR) on plasma MR-proADM level (30). However our results did not show 
a significant confounding effect by plasma creatinine on the association of IL6 SNP and 
ADM level (Table 2), while the association appears stronger in women without a significant 
sex interaction. There have been experimental studies reporting the effect of sex hormones 
on ADM expression. In rats, female sex hormone has been found to increase the expression 
of adrenomedullin-2 receptor (ADM2) and increase ADM-induced vasodilation (31). 
Plasma ADM levels are known to be raised in pregnancy (32), but none of our subjects were 
pregnant. ADM is expressed in the female gonads and reproductive tract (33). However, 
ADM is also expressed in the male reproductive organs including the testis, prostate and 
epididymis, and moreover, testosterone at physiological concentrations is reported to 
increase adrenomedullin production in human endothelial cells (34). Hence, the effect of 
sex on such an association cannot be confirmed in this study. The insufficient sample size 
may limit the statistical power to detect a significant interaction effect and significant 
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association in men. Therefore a larger sample is necessary to clarify the effect of sex on the 
association. Nevertheless, as ADM plays a key role in inflammation, cardiovascular disease 
and cancer, and its plasma level is an indicator of prognosis, elucidating the regulation of 
ADM warrants further studies. 
 
The minor allele of rs1717230 was associated with decreased HOMA-IR and less regular 
exercise. Although we expect a relationship between insulin resistance and frequent exercise 
(35), our study showed no correlation between HOMA-IR and frequent exercise (P=0.320). 
A possible reason for the discrepancy is that the regular exercise status in our analysis only 
takes the duration into account, but not the nature and intensity of exercise.  
 
In conclusion, plasma ADM levels are associated with the IL6 SNP rs17147230 in a Hong 
Kong Chinese population. Further work is needed in order to elucidate the mechanism and 
interactions of the SNP with the ADM gene to give rise to the change in plasma ADM 
levels. 
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Figure Legends 
Figure 1. A diagram showing the interleukin-6 gene (IL6). Exons and introns are shown as 
boxes and horizontal lines with the respective sizes indicated. The minor allele frequencies 
of the tagging single nucleotide polymorphisms (SNPs) in HapMap Han Chinese are 
indicated in brackets as shown above. 
 
Figure 2 Association of single nucleotide polymorphism (SNP) with plasma adrenomedullin 
levels. The error bars show 95% CI., of the mean. P values were calculated using natural 
log-transformed levels after adjusting for age and sex, and remained significant after 
multiple testing correction by permutation method.  
 
 22 
 
 
Table 1.  Subject characteristics according to genotypes of rs17147230 
Characteristics All subjects AA AT TT P for trend 
n 476 151 252 73 - 
Age (years) 50.9±10.8 51.7±11.2 50.5±10.9 50.9±9.4 0.461 
Women (%) 50.4 49.7 50.4 52.1 0.802 
BMI (kg/m2) 23.9±3.8 23.7±3.3 24.1±3.7 23.6±3.2 0.845 
Waist circumference (cm) 79.7±10.1 79.4±9.5 80.2±10.7 78.9±9.5 0.815 
SBP (mmHg) 122.8±18.1 123.4±17.7 122.6±18.0 122.2±19.4 0.869 
DBP (mmHg) 76.8±10.1 76.7±9.4 77.2±10.9 75.6±10.2 0.746 
Triglycerides (mmol/L)* 1.19 (1.10-1.27) 1.18 (1.08-1.28) 1.24 (1.16-1.33) 1.03 (0.92-1.16) 0.318 
HDL cholesterol (mmol/L) 1.37±0.39 1.41±0.41 1.35±0.38 1.39±0.35 0.360 
LDL cholesterol (mmol/L) 3.26±0.84 3.34±0.89 3.21±0.80 3.26±0.87 0.400 
Glucose 2 hours after OGTT 
(mmol/L)* 
6.83 (6.55-7.11) 6.79 (6.36-7.24) 7.00 (6.71-7.31) 6.38 (5.79-7.02) 0.478 
HOMA-IR* 1.72 (1.56-1.88) 1.82(1.65-2.01) 1.74(1.60-1.89) 1.48 (1.28-1.70) 0.045 
ADM (pmol/L)* 11.52 (11.03-12.00) 12.14 (11.26-13.02) 11.45 (10.78-12.12) 10.56 (9.44-11.67) 0.034 
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Adiponectin (mg/L)* 6.89 (6.44-7.34) 7.12(6.39-7.94) 6.50(6.00-7.04) 7.88(6.89-9.01) 0.588 
Fibrinogen (g/L) 2.92±0.53 2.90±0.56 2.93±0.54 2.95±0.47 0.331 
hsCRP (mg/L)* 0.56 (0.47-0.65) 0.53 (0.46-0.62) 0.57(0.51-0.65) 0.58(0.47-0.72) 0.423 
GGT (U/L)* 23.89 (21.47-26.31) 23.54 (21.29-26.02) 24.48(22.66-26.44) 22.64(19.59-26.16) 0.992 
ALP (U/L)* 68.18 (66.39-69.96) 67.68 (65.15-70.52) 69.13 (64.24-71.67) 65.94 (64.16-70.84) 0.997 
IL-6 (pg/L)* 0.47 (0.41-0.53) 0.45 (0.40-0.52) 0.51(0.46-0.57) 0.38(0.29-0.51) 0.504 
Creatinine (umol/L) 90.61±15.40 90.45±14.99 90.73±15.72 90.53±15.30 0.543 
Cardiovascular diseases (%) 4.6 4.6 5.2 2.7 0.844 
Current smoking (%) 18.9 20.5 18.3 17.8 0. 583 
Regular drinking (%) 10.3 10.7 10.2 10.0 0. 901 
Regular Exercise (%) 29.3 37.0 26.0 25.0 0.042 
Data are expressed as mean±SD or percentage  
P values were adjusted for age and sex 
*Variables with skewed distribution are expressed as geometric mean (95% CI). 
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; OGTT, oral glucose tolerance test; HOMA-IR, homeostatic model assessment of insulin resistance index; ADM, 
 24 
 
 
adrenomedullin; hsCRP, high-sensitivity C-reactive protein; GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; IL-6, interleukin-6 
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Table 2.  Association of the number of minor alleles in rs17147230 with plasma ADM  
 Model 1 Model 2 Model 3 Model 4 
n 476 436 411 377 
β* -0.096 -0.104 -0.109 -0.092 
P 0.034 0.031 0.030 0.077 
Adjusted r² 0.025 0.037 0.028 0.038 
Analysis was performed with plasma ADM (ln-transformed) as the dependent variable. 
Only the standardized β coefficient for the number of minor alleles present is shown. 
Model 1: Adjusted for age and sex 
Model 2: Further adjusted for biochemical parameters including BMI, HDL 
cholesterol ,SBP, fibrinogen and natural log of triglycerides, , HOMA-IR, post OGTT 
glucose level, hsCRP, adiponectin, ALP, GGT and plasma creatinine level 
Model 3: Further adjusted for lifestyle factors including regular drinking, smoking and 
exercise, and presence of cardiovascular diseases 
Model 4: Further adjusted for plasma IL-6 level (In-transformed) 
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; HDL, high-density 
lipoprotein; OGTT, oral glucose tolerance test; HOMA-IR, homeostatic model assessment 
of insulin resistance index; hsCRP, high-sensitivity C-reactive protein; GGT, 
gamma-glutamyltransferase; ALP, alkaline phosphatase; IL-6, interleukin-6 
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Figure 1 
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Figure2
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Online Supplementary Tables 
Supplementary Table S1.  Multivariate analysis of rs17147230 for plasma ADM levels (ln-transformed) 
Model Genotype All subjects (n = 476) Men (n = 236) Women (n = 240) 
  B (SE) P value B (SE) P value B (SE) P value 
Model 1 TT  -0.137 (0.067) 0.041 -0.022 (0.086) 0.799 -0.241 (0.102) 0.019  
 AT  -0.069 (0.048) NS -0.039 (0.061) NS -0.089 (0.075) NS 
 AA  referent - referent - referent - 
        
Model 2 TT -0.149 (0.070) 0.033 -0.028 (0.090) NS -0.266 (0.108) 0.014 
 AT -0.068 (0.051) NS -0.020 (0.067) NS -0.082 (0.078) NS 
 AA referent - referent - referent - 
Model 1: Adjusted for age and sex (adjusted for age only in sex-specific analysis) 
Model 2: Further adjusted for biochemical parameters including BMI, HDL cholesterol ,SBP, fibrinogen and natural log of triglycerides, , 
HOMA-IR, post OGTT glucose level, hsCRP, adiponectin, ALP, GGT and plasma creatinine level 
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; HDL, high-density lipoprotein; OGTT, oral glucose tolerance test; 
HOMA-IR, homeostatic model assessment of insulin resistance index; hsCRP, high-sensitivity C-reactive protein; ALP, alkaline phosphatase; 
GGT, gamma-glutamyltransferase 
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Supplementary Table S2.  Association of haplotype with plasma ADM level in women 
 
 
 
 
 
*Ominibus test was initially performed to assess the P value of the overall variation at the locus.  
ªAdjusted for age only 
 
 
Haplotype rs17147230 rs1800796 rs2069837 Frequency Beta P valueª Overall P* 
1 A C A 0.539 0.101 0.0471 0.056 
2 T C A 0.259 -0.114 0.0555  
3 T G G 0.117 -0.143 0.0693  
4 T G A 0.047 0.151 0.195  
5 A G G 0.033 0.0579 0.692  
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